Biogen reverses course on compassionate use for ALS drug tofersen with plans to open program in July
Despite immense pressure from the ALS community, Biogen had repeatedly refused to open investigational drug tofersen for use outside of clinical trials. But now, caving …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
